Within-trial hospitalization resource utilization and budget impact analysis for darolutamide in metastatic hormone-sensitive prostate cancer using ARASENS

• Published in: Journal of managed care & specialty pharmacy 2024-09, Vol.30 (9), p.991-1000
• Main Authors: Morgans, Alicia K., Grossman, Jamie Partridge, Paracha, Noman, Ladino, Daniel, Tyas, Emma, Rodriguez-Santamaria, Fernando, Shore, Neal
• Format: Article
• Language: English
• ISSN: 2376-0540; 2376-1032
• DOI: 10.18553/jmcp.2024.24045

This study shows that adding darolutamide to standard treatment does not make a patient more likely to go to the hospital each year. However, the time someone spends in the hospital may be longer. Patients are shown to go to the hospital more in the first 4 months of treatment. This could be due to docetaxel. Darolutamide is shown to be a cost-neutral option from a US hospitalization viewpoint over 5 years. This research can help inform US payers who may be reluctant to add darolutamide to docetaxel + ADT in an effort to contain costs. The key findings of our study demonstrate that adding darolutamide has a negligible impact on a payer’s costs per treated member per month over a 5-year period. As cost containment is becoming an even more important driver with the advent of the Inflation Reduction Act, payers have become increasingly cognizant of keeping these costs down.